Geocann Introduces Patent-Protected VESIsorb® Formulated Cannabis Products to the Global Marketplace
Natural products industry veteran launches cannabis company powered by an intellectual property portfolio with a successful track record of global distribution and a growing body of supporting science.
Geocann is proud to announce that the company has successfully leveraged a robust intellectual property portfolio by applying patented drug delivery system technologies to cannabinoid formulations that are distributed to the global marketplace through strategic partnerships with category-dominant brands.
“Geocann’s mission is to deliver safe and effective cannabinoid products that offer an extraordinary range of health benefits by building upon a legacy of pioneering science-backed natural ingredients formulated with innovative delivery system technologies,” Jesse Lopez, CEO and founder, said.
The bedrock of Geocann’s intellectual property portfolio is a multi-patented drug delivery system technology, trademarked VESIsorb®, that has a long history of safe and effective use worldwide. This Swiss technology has been clinically proven to increase the absorption and bioavailability of cannabinoids, including Cannabidiol (“CBD”), and is formulated in a broad range of product applications from capsules and sublinguals to topicals, beverages and foods.
“We are extremely pleased with the depth of VESIsorb® formulated cannabinoid product applications that Geocann has successfully brought to market,” Marc Weder, Chief Scientific Officer, said. “Each product was specifically designed to provide a solution to the formulation challenges faced by our brand partners.”
According to Weder, these formulations deliver higher cannabinoid blood plasma levels with a muchlower dose, and perhaps the most important benefit is a consistent, predictable and safer onset after consumption, often categorized as rapid uptake.
Lopez is also the founder of SourceOne Global Partners (Chicago, Illinois), a leading provider of health and wellness solutions with nearly two decades of experience pioneering the enhanced bioavailability of product formulations with scientific evidence and research partnerships. Lopez and Weder, founder, Vesifact AG (Zurich, Switzerland), have launched more than 50 VESIsorb®formulations since 2005.
VESIsorb®is the leading delivery system innovation for dramatically improving the bioavailability of poorly absorbed ingredients, like cannabinoids. Since 2005, the advancement and superiority of this colloidal droplet delivery system have consistently been demonstrated in well-designed pilot and peer reviewed published pharmacokinetic absorption and bioavailability studies as well a sthird-party meta-analyses. For more information, please visit www.vesisorb.com.